Recon: FDA rejects Novo Nordisk’s weekly insulin; Pfizer to develop once-daily GLP-1 weight-loss drug

• Novo Nordisk’s weekly insulin rejected by FDA (STAT)
• Biden administration ignores calls to bolster hospital price transparency (STAT)
• Researchers identify ‘molecular switch’ in lupus that could stymie harmful immune response (STAT)
• Pfizer presses forward with once-daily GLP-1 pill in long-awaited move (Endpoints)
• Novartis to shut down San Diego technical research and development facility (Endpoints)
• AbbVie CSO Tom Hudson to retire, replaced by medical chief (Endpoints)
• Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report (Pink Sheet)
• FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting (Pink Sheet)
• US FDA flags shortage of Becton Dickinson's blood test tubes (Reuters)
• US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices (Reuters)
• US FTC to sue drug middlemen over insulin prices, source says (Reuters)

• U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer (STAT)
• Ipsen takes on another ADC, this time from a China-based biotech (Endpoints)
• Almost all patients quit weight loss shots within two years, analysis finds (Endpoints)
• Thermo Fisher closes $3.1B Olink acquisition after UK antitrust review is cleared (Endpoints)
• Hong Kong Enhances Expedited Drug Licensing Process; Adopts Refuse-To-File Tool (Pink Sheet)
• EFPIA: EU Must Up The Budget Of Next R&D Funding Framework (Pink Sheet)
• Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio (Pink Sheet)

• Roche’s TIGIT study was a bust. What’s the outlook for its next big bet? (STAT)
• How the world's biggest pharma and biotech companies paid their typical worker in 2023 (Endpoints)
• Novo-partnered 3D bioprinting biotech gets $70M+ from Canadian government (Endpoints)
• Flagship's Noubar Afeyan on uncertainty, AI and biotech’s future (Endpoints)
• Are 'next-gen' biotech acquirers experiencing their moment? (Endpoints)
• Exclusive: Courier Health raises $16.5M Series A to help biopharma companies bring together patient data (Endpoints)
• Indivior shares dive on profit warning, dropping of schizophrenia drug (Reuters)
• Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts (Fierce Pharma)

• Musk's Neuralink says tiny wires of brain chip in first patient now stable (Reuters)
• Roche wins CE mark for its first CGM (MedTech Dive)
• Illumina buys Fluent Biosciences, adding single-cell analysis tech (MedTech Dive)
• Federal officials step down from health AI group’s board (MedTech Dive)
• Endoron Staples Down $10M To ‘Revolutionize’ Abdominal Aortic Aneurysm Repair (MedTech Insight)
• Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s Patients – Study (MedTech Insight)
• Orange Book Is The New Spat: FTC Seeks Removal Of ‘Improperly’ Listed Medical Device Patents (MedTech Insight)

• Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system (STAT)
• Medicaid is paying millions for salty, fat-laden ‘medically tailored’ cheeseburgers and sandwiches (STAT)
• Doctors ‘overprescribing’ opioids isn’t the cause of the overdose epidemic — and it never was (STAT)
• Preparing schools for the H5N1 bird flu they’re likely to face (STAT)
• US FDA’s Genetic Metabolic Diseases Adcomm Debuts With Zevra’s Arimoclomol (Pink Sheet)
• Power to the Patient with Patient Generated Health Data (FDA Law Blog)